US 12,187,753 B2
Therapeutics compounds for HIV virus infection
Julie Farand, San Mateo, CA (US); Tezcan Guney, Foster City, CA (US); Darryl Kato, San Francisco, CA (US); John O. Link, San Francisco, CA (US); James B. C. Mack, San Mateo, CA (US); and William J. Watkins, Saratoga, CA (US)
Assigned to Gilead Sciences, Inc., Foster City, CA (US)
Filed by Gilead Sciences, Inc., Foster City, CA (US)
Filed on Aug. 22, 2023, as Appl. No. 18/236,532.
Application 18/236,532 is a continuation of application No. 18/061,375, filed on Dec. 2, 2022, granted, now 11,787,825.
Claims priority of provisional application 63/356,889, filed on Jun. 29, 2022.
Claims priority of provisional application 63/285,730, filed on Dec. 3, 2021.
Prior Publication US 2024/0132527 A1, Apr. 25, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07F 9/09 (2006.01)
CPC C07F 9/095 (2013.01) 40 Claims
 
1. A compound that is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.
 
2. A compound that is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.
 
3. A compound that is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.
 
4. A compound that is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.
 
5. A compound that is

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof.